119 related articles for article (PubMed ID: 16108245)
21. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
Fraunfelder FW; Winthrop K; Suhler E; Choi D; Fraunfelder FT
Retina; 2009 Feb; 29(2):285-6; author reply 286-7. PubMed ID: 19202428
[No Abstract] [Full Text] [Related]
22. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
23. Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report.
Huang HT; Kang L; Huang PJ; Fu YC; Lin SY; Hsieh CH; Chen JC; Cheng YM; Chen CH
Menopause; 2012 Dec; 19(12):1360-3. PubMed ID: 22968250
[TBL] [Abstract][Full Text] [Related]
24. Bisphosphonates and the risk of atrial fibrillation.
Sewerynek E; Stuss M
Endokrynol Pol; 2011; 62(1):93-6. PubMed ID: 21365587
[TBL] [Abstract][Full Text] [Related]
25. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
26. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
[TBL] [Abstract][Full Text] [Related]
27. [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
Ringe JD
MMW Fortschr Med; 2009 Mar; 151(10):7. PubMed ID: 19472655
[No Abstract] [Full Text] [Related]
28. Scleritis and other ocular side effects associated with pamidronate disodium.
Fraunfelder FW; Fraunfelder FT; Jensvold B
Am J Ophthalmol; 2003 Feb; 135(2):219-22. PubMed ID: 12566027
[TBL] [Abstract][Full Text] [Related]
29. [Alendronate-induced severe esophagitis. A rare and severe reversible side-effect illustrated by three case reports].
Tóth E; Fork FT; Lindelöw K; Lindström E; Verbaan H; Veress B
Lakartidningen; 1998 Aug; 95(35):3676-80. PubMed ID: 9748782
[TBL] [Abstract][Full Text] [Related]
30. [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment].
Bartl R; Götte S; Hadji P; Hammerschmidt T
Dtsch Med Wochenschr; 2006 Jun; 131(22):1257-62. PubMed ID: 16755420
[TBL] [Abstract][Full Text] [Related]
31. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
[TBL] [Abstract][Full Text] [Related]
32. Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study.
Chiang CH; Huang CC; Chan WL; Huang PH; Chen TJ; Chung CM; Lin SJ; Chen JW; Leu HB
J Bone Miner Res; 2012 Sep; 27(9):1951-8. PubMed ID: 22532232
[TBL] [Abstract][Full Text] [Related]
33. [Bisphosphonate therapy in osteoporosis. Inhibition of trabecular perforation by aminobisphosphonate].
Wüster C; Heilmann P
Fortschr Med; 1997 Oct; 115(29):37-42. PubMed ID: 9445833
[TBL] [Abstract][Full Text] [Related]
34. Pharmaceutical care issues encountered by post-menopausal osteoporotic women prescribed bisphosphonates.
Lai PS; Chua SS; Chan SP
J Clin Pharm Ther; 2012 Oct; 37(5):536-43. PubMed ID: 22380577
[TBL] [Abstract][Full Text] [Related]
35. Is your knowledge up-to-date? Bisphosphonate-related osteonecrosis of the jaw.
Barrow SY
Int J Dent Hyg; 2008 Nov; 6(4):376-7. PubMed ID: 19138190
[No Abstract] [Full Text] [Related]
36. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Cramer JA; Amonkar MM; Hebborn A; Altman R
Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
[TBL] [Abstract][Full Text] [Related]
37. [Alendronate].
Sørensen HA; Hyldstrup L
Ugeskr Laeger; 1998 May; 160(22):3240-3. PubMed ID: 9621809
[No Abstract] [Full Text] [Related]
38. Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report.
Wang HL; Weber D; McCauley LK
J Periodontol; 2007 Mar; 78(3):584-94. PubMed ID: 17335384
[TBL] [Abstract][Full Text] [Related]
39. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
40. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study.
Etminan M; Forooghian F; Maberley D
CMAJ; 2012 May; 184(8):E431-4. PubMed ID: 22470169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
